Cigna Group (NYSE:CI) Stock Keeps Outperform Rating at Royal Bank Of Canada

Cigna Group (NYSE:CI)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Royal Bank Of Canada in a research report issued on Thursday, Benzinga reports. They presently have a $337.00 price target on the health services provider’s stock. Royal Bank Of Canada’s price objective suggests a potential upside of 25.55% from the company’s current price.

A number of other equities research analysts have also recently issued reports on the stock. Wolfe Research reaffirmed an “outperform” rating and issued a $315.00 target price on shares of Cigna Group in a report on Tuesday, June 16th. Evercore assumed coverage on shares of Cigna Group in a research note on Wednesday, September 9th. They issued an “in-line” rating and a $290.00 price target on the stock. Robert W. Baird set a $362.00 price target on shares of Cigna Group in a research note on Friday, July 31st. Wells Fargo & Company upped their price target on shares of Cigna Group from $305.00 to $307.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st. Finally, Raymond James Financial lowered shares of Cigna Group from a “strong-buy” rating to an “outperform” rating and decreased their price target for the company from $350.00 to $320.00 in a research note on Monday, August 3rd. Fifteen analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $337.10.

Cigna Group Stock Performance

Shares of CI stock traded down $3.42 on Thursday, reaching $268.41. The stock had a trading volume of 1,980,848 shares, compared to its average volume of 1,684,883. The company has a quick ratio of 0.76, a current ratio of 0.76 and a debt-to-equity ratio of 0.68. The firm’s 50-day moving average is $279.18 and its two-hundred day moving average is $280.56. The firm has a market capitalization of $70.92 billion, a price-to-earnings ratio of 11.11, a P/E/G ratio of 0.93 and a beta of 0.31. Cigna Group has a 12 month low of $239.51 and a 12 month high of $315.47.

Cigna Group (NYSE:CI) last issued its earnings results on Thursday, July 30th. The health services provider reported $7.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.60 by $0.18. The company had revenue of $71.56 billion for the quarter, compared to analysts’ expectations of $70.14 billion. Cigna Group had a net margin of 2.27% and a return on equity of 19.75%. Cigna Group’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $7.20 EPS. Cigna Group has set its FY 2026 guidance at 30.450- EPS. On average, research analysts expect that Cigna Group will post 30.51 EPS for the current fiscal year.

Insider Transactions at Cigna Group

In related news, insider Nicole Jones sold 19,436 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $276.27, for a total value of $5,369,583.72. Following the transaction, the insider owned 27,256 shares in the company, valued at approximately $7,530,015.12. This represents a 41.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Everett Neville sold 617 shares of the stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $284.05, for a total transaction of $175,258.85. Following the transaction, the insider owned 5,053 shares in the company, valued at approximately $1,435,304.65. The trade was a 10.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 22,730 shares of company stock worth $6,293,359. 0.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CI. Osbon Capital Management LLC acquired a new position in shares of Cigna Group during the 2nd quarter worth approximately $26,000. Cedar Mountain Advisors LLC grew its position in shares of Cigna Group by 161.9% during the 1st quarter. Cedar Mountain Advisors LLC now owns 110 shares of the health services provider’s stock worth $29,000 after purchasing an additional 68 shares in the last quarter. Johnson Financial Group Inc. acquired a new position in shares of Cigna Group during the 2nd quarter worth approximately $29,000. Fiduciary Financial Advisors acquired a new position in shares of Cigna Group during the 2nd quarter worth approximately $29,000. Finally, ANTIPODES PARTNERS Ltd acquired a new position in shares of Cigna Group during the 2nd quarter worth approximately $34,000. Institutional investors and hedge funds own 86.99% of the company’s stock.

Cigna Group News Summary

Here are the key news stories impacting Cigna Group this week:

• Positive Sentiment: Cigna introduced its “Lead to One” strategy, focusing on complex care, specialty pharmacy, clinical expertise, data, technology and artificial intelligence. Management is targeting 10%–14% adjusted EPS compound annual growth through 2030, which supports the long-term investment case. Cigna Investor Day announcement
• Positive Sentiment: The company plans to invest approximately $3 billion in a multiyear modernization, workflow and productivity initiative. Cigna expects the spending to improve operations and support performance over time, although it may weigh on near-term results. Forbes specialty pharmacy investment article
• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and set a $337 price target, implying substantial upside from the current trading level. Analysts and Seeking Alpha commentary also describe CI as undervalued, citing expected double-digit EPS growth. Cigna valuation analysis
• Neutral Sentiment: Cigna reaffirmed its fiscal 2026 adjusted EPS guidance of approximately $30.45 and continues to pursue international growth, including an arrangement involving UnitedHealthcare. The guidance confirmation reduces uncertainty but did not provide a major upward revision. Cigna international business article
• Negative Sentiment: Fiscal 2026 revenue guidance of $280 billion is below the roughly $287.2 billion analyst consensus, while EPS guidance of $30.45 is slightly under the $30.51 consensus. This near-term shortfall, combined with the cost of the $3 billion initiative, appears to be pressuring the stock despite the stronger long-term outlook. Cigna financial targets article

About Cigna Group

The Cigna Group (NYSE: CI) is a global health company that provides health care and related services to individuals, employers, government organizations and health plans. Its operations are primarily organized through Cigna Healthcare and Evernorth Health Services, which together address health coverage, pharmacy services, care delivery and benefit management.

Cigna Healthcare offers medical, dental, behavioral health, disability and other benefits, with a focus on employer-sponsored and individual health plans in the United States as well as international health services.